Kai Chu

5.4k citations

60 papers · 3.2k · 1 hit paper · h-index 23

Impact in

Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Outbreaks Research
- COVID-19 Clinical Research Studies
Cardiology and Cardiovascular Medicine top 5%
- Viral Infections and Immunology Research

Papers in

Infectious Diseases 16
- SARS-CoV-2 and COVID-19 Research 10
- Viral Infections and Outbreaks Research 4
- Antimicrobial Resistance in Staphylococcus 2
Epidemiology 21
- Cervical Cancer and HPV Research 13
- Influenza Virus Research Studies 5

Co-authors: Fengcai Zhu (23 shared papers)Yuemei Hu (22 shared papers)Jingxin Li (14 shared papers)Fanyue Meng (10 shared papers)Hongxing Pan (12 shared papers)Jialei Hu (11 shared papers)Deyu Jiang (4 shared papers)Weidong Yin (2 shared papers)
Journals: Human Vaccines & Immunotherapeutics (14 papers)Vaccine (6 papers)The Lancet Infectious Diseases (5 papers)The Lancet (3 papers)The Journal of Infectious Diseases (3 papers)
Partner nations: China United States Philippines

In The Last Decade

Kai Chu

55 papers receiving 3.1k citations

Kai Chu's Hit Papers

align trajectories log scale

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial 2020 · 1.2k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2020 The Lancet Infectious Diseases

Peers

Countries citing papers authored by Kai Chu

Since Specialization

Citations

This map shows the geographic impact of Kai Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Chu more than expected).

Fields of papers citing papers by Kai Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Chu. The network helps show where Kai Chu may publish in the future.

Co-authors

The 25 scholars most cited alongside Kai Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kai Chu Line = papers co-authored together Kai Chu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial The Lancet Infectious Diseases ·Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Biao Kan, Kai Chu, 茅海燕, Qianqian Xin Hit paper breakdown →	2020	1164
2	Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial The Lancet ·Fengcai Zhu, Fanyue Meng, Jingxin Li, Xiuling Li, Qunying Mao, Yuntao Zhang, Xin Yao, Kai Chu	2013	341
3	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials The Lancet Infectious Diseases ·Gang Zeng, Qianhui Wu, Hongxing Pan, Minjie Li, Juan Yang, Lin Wang, Zhiwei Wu, Deyu Jiang	2021	249
4	Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial The Lancet ·Fengcai Zhu, Lihua Hou, Jingxin Li, Shipo Wu, Pei Liu, Gui-Rong Zhang, Yuemei Hu, Fanyue Meng	2015	150
5	Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial JNCI Journal of the National Cancer Institute ·You‐Lin Qiao, Ting Wu, Rongcheng Li, Yuemei Hu, Lihui Wei, Changgui Li, Wen Chen, Shoujie Huang	2019	133
6	Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials The Lancet Respiratory Medicine ·Fengcai Zhu, Chunlan Zhuang, Kai Chu, Liang Zhang, Hui John Zhao, Shoujie Huang, Yingying Su, Hong‐Yan Lin	2022	114
7	Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial The Lancet Global Health ·Jingxin Li, Lihua Hou, Fanyue Meng, Shipo Wu, Yuemei Hu, Qi Liang, Kai Chu, Zhe Zhang	2016	86
8	Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial The Lancet ·Fengcai Zhu, Zhenglun Liang, Xiuling Li, Heng-Ming Ge, Fanyue Meng, Qunying Mao, Yuntao Zhang, Yuemei Hu	2013	81
9	Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial The Lancet Infectious Diseases ·Fang-Hui Zhao, Ting Wu, Yuemei Hu, Lihui Wei, Mingqiang Li, Weijin Huang, Wen Chen, Shoujie Huang	2022	66
10	Retrospective Study of the Incidence of HFMD and Seroepidemiology of Antibodies against EV71 and CoxA16 in Prenatal Women and Their Infants PLoS ONE ·Fengcai Zhu, Zhenglun Liang, Fanyue Meng, Ying Zi Zeng, Qunying Mao, Kai Chu, Xue-Fang Song, Xin Yao	2012	63
11	High Prevalence of Schistosoma japonicum Infection in Water Buffaloes in the Philippines Assessed by Real-Time Polymerase Chain Reaction American Journal of Tropical Medicine and Hygiene ·Hai-Wei Wu, Yuan-Fang Qin, Kai Chu, Yun Liu, Stephen T. McGarvey, Remigio M. Olveda, Luz P. Acosta, Minjun Ji	2010	61
12	2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study The Journal of Infectious Diseases ·Mingwei Wei, Fanyue Meng, Shiyuan Wang, Jingxin Li, Yuntao Zhang, Qunying Mao, Yuemei Hu, Pei Liu	2016	61
13	Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women Science China Life Sciences ·Yuemei Hu, Meng Guo, Changgui Li, Kai Chu, Wengang He, Jing Zhang, Juan Li, Hui John Zhao	2019	46
14	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials Chinese Medical Journal ·Hongxing Pan, Jiankai Liu, Baoying Huang, Guifan Li, Xianyun Chang, Yafei Liu, Wenling Wang, Kai Chu	2021	44
15	Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children Human Vaccines & Immunotherapeutics ·Fanyue Meng, Jingxin Li, Xiuling Li, Kai Chu, Yuntao Zhang, Hong Long Ji, Liang Li, Zhenglun Liang	2012	38
16	Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation Human Vaccines & Immunotherapeutics ·Yuemei Hu, Gang Zeng, Kai Chu, Jing Zhang, Weixiao Han, Ying Zhang, Jing Li, Fengcai Zhu	2018	33
17	Safety of anEscherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine Human Vaccines & Immunotherapeutics ·Yuemei Hu, Shoujie Huang, Kai Chu, Ting Wu, Zhongze Wang, Changlin Yang, Jia-Ping Cai, Han-Min Jiang	2013	32
18	Immunogenicity and Safety of a Sabin Strain–Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial The Journal of Infectious Diseases ·Yuemei Hu, Jianfeng Wang, Gang Zeng, Kai Chu, Deyu Jiang, Feng-Dong Zhu, Zhifang Ying, Lei Chen	2019	28
19	Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial The Lancet Infectious Diseases ·Fengcai Zhu, Guo‐Hua Zhong, Weijin Huang, Kai Chu, Li Zhang, Zhaofeng Bi, Kongxin Zhu, Qi Chen	2023	28
20	Reactogenicity and Immunogenicity of an Enterovirus 71 Vaccine in Chinese Healthy Children and Infants The Pediatric Infectious Disease Journal ·Fengcai Zhu, Junzhi Wang, Xiuling Li, Zhenglun Liang, Heng-Ming Ge, Fanyue Meng, Qunying Mao, Yuntao Zhang	2012	27

About Kai Chu

Kai Chu is a scholar working on Infectious Diseases, Epidemiology, Cardiology and Cardiovascular Medicine, Parasitology and Critical Care and Intensive Care Medicine, having authored 60 papers that have together received 3.2k indexed citations. Recurring topics across this work include Viral Infections and Immunology Research (16 papers), Cervical Cancer and HPV Research (13 papers), SARS-CoV-2 and COVID-19 Research (10 papers), Influenza Virus Research Studies (5 papers), Parasites and Host Interactions (4 papers), Viral Infections and Outbreaks Research (4 papers), Yersinia bacterium, plague, ectoparasites research (2 papers) and Antimicrobial Resistance in Staphylococcus (2 papers). The work is most often cited by research in Infectious Diseases (1.8k citations), Cardiology and Cardiovascular Medicine (613 citations), Epidemiology (462 citations), Parasitology (75 citations) and Health (88 citations). Kai Chu has collaborated with scholars based in China, United States and Philippines. Frequent co-authors include Fengcai Zhu, Yuemei Hu, Jingxin Li, Fanyue Meng, Hongxing Pan, Jialei Hu, Deyu Jiang, Weidong Yin, Bihua Han and Qianhui Wu. Their work appears in journals such as Human Vaccines & Immunotherapeutics, Vaccine, The Lancet Infectious Diseases, The Lancet and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Kai Chu

Impact in

Papers in i

In The Last Decade

Kai Chu

Kai Chu's Hit Papers

Peers

Countries citing papers authored by Kai Chu

Fields of papers citing papers by Kai Chu

All Works

About Kai Chu

Explore authors with similar magnitude of impact

Papers in